Pre-surgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer

10 Nov 2016


Neoadjuvant endocrine therapy - designed to reduce the size of breast tumours before surgical removal - appears to be as effective as neoadjuvant chemotherapy for patients with localized, oestrogen-receptor (ER)-positive breast cancer with considerably fewer side effects. The study was published in JAMA Oncology.

Medical XPress


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story